Have a feature idea you'd love to see implemented?
Let us know!
VKTX Viking Therapeutics Inc
Price (delayed)
$42.655
Market cap
$4.75B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.93
Enterprise value
$4.7B
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and
Highlights
VKTX's equity has surged by 148% year-on-year
The company's quick ratio rose by 29% YoY but it fell by 3.5% QoQ
Viking Therapeutics's debt has increased by 12% QoQ but it has decreased by 8% YoY
The net income fell by 23% YoY and by 2.5% QoQ
Key stats
What are the main financial stats of VKTX
Market
Valuations
Earnings
Shares outstanding
111.44M
Market cap
$4.75B
Enterprise value
$4.7B
Price to earnings (P/E)
N/A
Price to book (P/B)
5.19
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$99.15M
EBIT
-$99.15M
EBITDA
-$98.84M
Free cash flow
-$74.25M
Per share
Balance sheet
Liquidity
EPS
-$0.93
EPS diluted
-$0.93
Free cash flow per share
-$0.67
Book value per share
$8.23
Revenue per share
$0
TBVPS
$8.46
Total assets
$937.89M
Total liabilities
$26.44M
Debt
$1.24M
Equity
$911.45M
Working capital
$910.96M
Debt to equity
0
Current ratio
36.47
Quick ratio
36.23
Net debt/EBITDA
0.5
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-12.3%
Return on equity
-12.7%
Return on invested capital
-14.3%
Return on capital employed
-10.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VKTX stock price
How has the Viking Therapeutics stock price performed over time
Intraday
0.72%
1 week
2.81%
1 month
-20.15%
1 year
122.86%
YTD
129.2%
QTD
-32.63%
Financial performance
How have Viking Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$133.97M
Net income
-$99.15M
Gross margin
N/A
Net margin
N/A
Viking Therapeutics's operating income has decreased by 46% YoY and by 7% from the previous quarter
The net income fell by 23% YoY and by 2.5% QoQ
Growth
What is Viking Therapeutics's growth rate over time
Valuation
What is Viking Therapeutics stock price valuation
P/E
N/A
P/B
5.19
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
VKTX's equity has surged by 148% year-on-year
The P/B is 47% more than the 5-year quarterly average of 3.5 but 27% less than the last 4 quarters average of 7.1
Efficiency
How efficient is Viking Therapeutics business performance
The ROIC has soared by 61% year-on-year and by 17% since the previous quarter
Viking Therapeutics's ROE has soared by 59% YoY and by 15% from the previous quarter
VKTX's ROA has soared by 58% year-on-year and by 15% since the previous quarter
Dividends
What is VKTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VKTX.
Financial health
How did Viking Therapeutics financials performed over time
The total assets has soared by 145% YoY
VKTX's total liabilities has soared by 83% YoY and by 2.2% from the previous quarter
Viking Therapeutics's debt is 100% lower than its equity
VKTX's equity has surged by 148% year-on-year
Viking Therapeutics's debt has increased by 12% QoQ but it has decreased by 8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.